Study to Learn More About the Safety and Effectiveness of Rivaroxaban (Xarelto) When Given Together With Acetylsalicylic Acid to Indian People With Narrowing of the Arteries of the Heart (CAD) and/or With Reduced Blood Flow in the Arteries of the Legs and Arms With Symptoms (Symptomatic PAD)

CompletedOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

February 25, 2022

Primary Completion Date

March 28, 2024

Study Completion Date

June 6, 2024

Conditions

Prevention of Atherothrombotic EventsCoronary Artery Disease (CAD)Symptomatic Peripheral Artery Disease (Symptomatic PAD)

Interventions

DRUG

Rivaroxaban (Xarelto,Bay 59-7939)

Rivaroxaban (2.5 mg \[BID\])

DRUG

Acetylsalicylic acid(ASA)

ASA (75mg \[QD\]; dose according to local label.

Trial Locations (1)

Many locations, Multiple Locations